SCHEMBL18324705

SCHEMBL18324705

Cc1ccc(S(=O)(=O)N2CCC(c3c[nH]c4ccccc34)CC2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
BRD4 O60885 1/20 0.52
ALDH1A1 P00352 1/20 0.52
POLB P06746 1/20 0.52
CREBBP Q92793 1/20 0.52
MAPT P10636 3/20 0.49
PAX8 Q06710 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ATM Q13315 1/20 0.49
HTR7 P34969 2/20 0.48
ADRA1B P35368 1/20 0.48
IKBKB O14920 1/20 0.48
CHUK O15111 1/20 0.48
HTR2C P28335 2/20 0.45
ADRB2 P07550 1/20 0.45
HTR6 P50406 2/20 0.45
ADRA1D P25100 2/20 0.45
HSD11B1 P28845 1/20 0.44
DRD2 P14416 1/20 0.44
HTR2A P28223 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18325013 0.92 KDM4E (0.53) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324980 0.86 KDM4E (0.56) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324695 0.84 ALDH1A1 (0.55) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324710 0.84 KDM4E (0.57) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL20016366 0.83 ALDH1A1 (0.49) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324702 0.81 ALDH1A1 (0.53) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324983 0.80 KDM4E (0.52) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324679 0.79 KDM4E (0.64) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL18324801 0.77 KDM4E (0.61) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL25252905 0.77 TSHR (0.54) KDM4EBRD4ALDH1A1POLBCREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3082802-B1 TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE IOMET PHARMA LTD (GB) 2020-02-26 EP disclosed
US-9931347-B2 Pharmaceutical compound IOMET PHARMA LTD. (US) 2018-04-03 US disclosed
US-9931347-B2 Pharmaceutical compound IOMET PHARMA LTD. (US) 2018-04-03 US disclosed
US-20160367564-A1 Pharmaceutical Compound IOMET PHARMA LTD. (GB) 2016-12-22 US disclosed
US-20160367564-A1 Pharmaceutical Compound IOMET PHARMA LTD. (GB) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367564-A1 Pharmaceutical Compound TDO2, IDO1, IDO2 KDM4E 465/4885BRD4 1542/4885ALDH1A1 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.